- Home
- JAGX vs SNSE Comparison
JAGX vs SNSE Comparison
Compare JAGX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- SNSE
- Stock Information
- Founded
- JAGX 2013
- SNSE 2005
- Country
- JAGX United States
- SNSE United States
- Employees
- JAGX N/A
- SNSE N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- SNSE Health Care
- Exchange
- JAGX Nasdaq
- SNSE Nasdaq
- Market Cap
- JAGX 12.9M
- SNSE 12.5M
- IPO Year
- JAGX N/A
- SNSE 2021
- Fundamental
- Price
- JAGX $0.85
- SNSE $0.53
- Analyst Decision
- JAGX
- SNSE Strong Buy
- Analyst Count
- JAGX 0
- SNSE 3
- Target Price
- JAGX N/A
- SNSE $4.33
- AVG Volume (30 Days)
- JAGX 542.5K
- SNSE 769.5K
- Earning Date
- JAGX 11-13-2024
- SNSE 02-26-2025
- Dividend Yield
- JAGX N/A
- SNSE N/A
- EPS Growth
- JAGX N/A
- SNSE N/A
- EPS
- JAGX N/A
- SNSE N/A
- Revenue
- JAGX $10,480,000.00
- SNSE N/A
- Revenue This Year
- JAGX $18.18
- SNSE N/A
- Revenue Next Year
- JAGX $40.06
- SNSE N/A
- P/E Ratio
- JAGX N/A
- SNSE N/A
- Revenue Growth
- JAGX N/A
- SNSE N/A
- 52 Week Low
- JAGX $0.84
- SNSE $0.38
- 52 Week High
- JAGX $21.60
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- JAGX 39.11
- SNSE 56.84
- Support Level
- JAGX $0.84
- SNSE $0.47
- Resistance Level
- JAGX $1.33
- SNSE $0.55
- Average True Range (ATR)
- JAGX 0.10
- SNSE 0.05
- MACD
- JAGX -0.03
- SNSE 0.00
- Stochastic Oscillator
- JAGX 1.04
- SNSE 65.98
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.